These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28790113)

  • 1. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
    Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
    Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
    Zhang Y; Zhu S; Yi L; Liu Y; Cui H
    Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.
    Dong Z; Lei Q; Yang R; Zhu S; Ke XX; Yang L; Cui H; Yi L
    Br J Cancer; 2017 Jun; 116(12):1572-1584. PubMed ID: 28494471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth.
    Tokumoto H; Setoguchi T; Saitoh Y; Sasaki H; Nagano S; Maeda S; Tanimoto A; Taniguchi N
    Mol Carcinog; 2019 Dec; 58(12):2230-2240. PubMed ID: 31478563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
    Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
    Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients.
    Ouyang Q; Gong X; Xiao H; Zhou J; Xu M; Dai Y; Xu L; Feng H; Cui H; Yi L
    Mol Cancer; 2015 Feb; 14():21. PubMed ID: 25644759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody.
    Wu Z; Fournel L; Stadler N; Liu J; Boullier A; Hoyeau N; Fléjou JF; Duchatelle V; Djebrani-Oussedik N; Agopiantz M; Ségal-Bendirdjian E; Gompel A; Alifano M; Melander O; Trédaniel J; Forgez P
    Cancer Lett; 2019 Mar; 444():147-161. PubMed ID: 30583074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
    Wang H; Zhu L; Gao J; Hu Z; Lin B
    Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
    Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
    PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
    Ouyang Q; Chen G; Zhou J; Li L; Dong Z; Yang R; Xu L; Cui H; Xu M; Yi L
    Neuro Oncol; 2016 Feb; 18(2):216-26. PubMed ID: 26180082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 15. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
    Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
    Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
    Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
    Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
    Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Shu T; Li Y; Wu X; Li B; Liu Z
    Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
    Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
    BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.